Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Receivables - Other (2018 - 2025)

Historic Receivables - Other for Arrowhead Pharmaceuticals (ARWR) over the last 11 years, with Q4 2025 value amounting to $9.8 million.

  • Arrowhead Pharmaceuticals' Receivables - Other changed N/A to $9.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $9.8 million, marking a year-over-year change of. This contributed to the annual value of $4.8 million for FY2022, which is 5200.0% down from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Receivables - Other stood at $9.8 million for Q4 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Receivables - Other peaked at $25.0 million during Q4 2022, and registered a low of $100000.0 during Q4 2021.
  • Its 4-year average for Receivables - Other is $5.9 million, with a median of $1.5 million in 2023.
  • Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 9878.05% in 2021, then surged by 2490000.0% in 2022.
  • Over the past 4 years, Arrowhead Pharmaceuticals' Receivables - Other (Quarter) stood at $100000.0 in 2021, then soared by 24900.0% to $25.0 million in 2022, then tumbled by 94.0% to $1.5 million in 2023, then soared by 555.13% to $9.8 million in 2025.
  • Its Receivables - Other was $9.8 million in Q4 2025, compared to $1.5 million in Q2 2023 and $25.0 million in Q4 2022.